### Findings Index
- P1 | PER-1 | "Question" | Map/territory confusion — benchmark scores are treated as proxy for review quality, but LLM benchmarks don't measure structured analytical output
- P2 | PER-2 | "Current Cost Model" | Availability heuristic on Chinese model pricing — recent dramatic price drops create anchoring on price as the primary selection criterion
- P2 | PER-3 | "Question" | Streetlight effect — the proposal focuses on the measurable dimension (cost) while the harder-to-measure dimension (insight novelty) gets vague treatment
- P3 | PER-4 | "Question" | Goodhart's Law risk — if finding count becomes the quality metric, cheaper models that produce more lower-quality findings will appear cost-effective
Verdict: needs-changes

### Summary

The document's analytical frame is dominated by a cost reduction narrative, with model diversity as a secondary justification. This framing creates several sensemaking risks. First, it treats benchmark scores as proxies for review quality — but no benchmark measures "can this model produce a structured Findings Index with accurate severity ratings for a codebase it's never seen?" Second, the dramatic price drops of Chinese models create an availability heuristic where price becomes the dominant selection criterion, overshadowing quality dimensions that are harder to measure. Third, the insight novelty dimension — the most valuable potential outcome — gets the least analytical depth ("disagreements might be more meaningful") because it's harder to quantify than cost savings.

### Issues Found

PER-1. **P1: Benchmarks don't predict review quality.** The document's implicit logic chain is: "DeepSeek V3 scores well on benchmarks → it should produce good review findings → we can save money by routing agents to it." But the benchmarks that DeepSeek V3 excels at (MMLU, HumanEval, MATH) measure knowledge recall and code generation — not structured analytical output with severity calibration, evidence citation, and domain-specific lens application. The interflux agent task is unusual: produce a markdown document in a specific format, with findings tied to specific file locations, calibrated to a specific severity scale, from a specific cognitive lens. No benchmark measures this. The only valid proxy is empirical testing with actual interflux agent prompts.

**What's missing from the analysis:** The document should explicitly state that benchmark scores are not predictive of review quality, and that the only valid evidence is A/B testing with real review prompts. This reframes the decision from "which benchmarks show these models are good enough?" to "what does the minimum viable experiment look like?"

PER-2. **P2: Price anchoring.** DeepSeek V3's pricing story is dramatic — $0.27/M input vs Claude Opus at $15/M — and this dramatic contrast creates an availability heuristic. The price comparison is the first thing anyone notices, and it anchors the entire analysis. But price is the most volatile dimension: it changes monthly, varies by provider, and doesn't account for effective cost (retries, false positive review time, prompt engineering investment). The analysis should lead with the quality question ("do these models produce useful findings?") and introduce price only after quality is established as adequate.

PER-3. **P2: Measurability bias.** Cost savings are easy to measure: tokens * price/token. Insight novelty is hard to measure: how do you quantify "this review found something that a Claude-only review would have missed?" The proposal naturally gravitates toward the measurable dimension. But the insight novelty dimension is where the highest value lies — if model diversity genuinely surfaces blind spots that same-provider fleets miss, that's worth far more than the token cost savings. The document needs a concrete measurement protocol for insight novelty: e.g., "run 10 reviews with Claude-only, run the same 10 with mixed models, have a human reviewer score which found more actionable issues."

PER-4. **P3: Goodhart's Law on finding count.** If the quality metric for cheaper models becomes "number of findings produced," cheaper models that generate more findings (even lower-quality ones) will appear cost-effective. This is a classic Goodhart's Law scenario — the measure becomes the target. DeepSeek and Qwen models tend to produce verbose, comprehensive responses that may contain more bullet points but less analytical depth per finding. A quality metric should weight by confirmed severity: only P0/P1 findings that survive synthesis deduplication and human review count toward the quality baseline.

### Improvements

PER-I1. Lead the analysis with the quality question, not the cost question. Restructure the document: Section 1: "Can non-Claude models produce useful review findings?" → Section 2: "How much does model diversity improve insight quality?" → Section 3: "What are the cost implications?"

PER-I2. Define the insight novelty measurement protocol before starting implementation. Without it, the team will default to measuring cost savings and declaring success based on price reduction alone.

--- VERDICT ---
STATUS: warn
FILES: 0 changed
FINDINGS: 4 (P0: 0, P1: 1, P2: 2, P3: 1)
SUMMARY: The document's analytical frame is anchored on cost reduction, underweighting the harder-to-measure insight novelty dimension. Benchmark scores don't predict review quality — only empirical A/B testing with actual agent prompts can validate the core assumption. Lead with quality, not cost.
---
<!-- flux-drive:complete -->
